Results 61 to 70 of about 1,042 (177)

Treatments for chronic pruritus outside of the box [PDF]

, 2019
Patients with chronic pruritus are in desperate need of novel treatment options, as current therapeutic possibilities are often not effective, have a poor level of evidence and are mostly off-label.
Almustafa Z. Z., Buttgereit T., Calugareanu A., Mollanazar N. K., Schneider G., Ständer S.   +5 more
core   +1 more source

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

New England Journal of Medicine, 2020
Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight ...
Sonja, Ständer, Gil, Yosipovitch, Franz J, Legat, Jean-Philippe, Lacour, Carle, Paul, Joanna, Narbutt, Thomas, Bieber, Laurent, Misery, Andreas, Wollenberg, Adam, Reich, Faiz, Ahmad, Christophe, Piketty   +11 more
openaire   +2 more sources

24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Journal of Dermatological Treatment
Backgrounds Prurigo nodularis (PN) is a chronic pruritic inflammatory disease associated with immune and neural dysregulation. Although nemolizumab has demonstrated efficacy in clinical trials, real-world post-marketing data remain limited.Objective To ...
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +1 more source

Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence

Journal of Dermatological Treatment
Background Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain.Objective To synthesize efficacy, safety and strength of evidence for ...
Mohammed Shanshal, Aarthy Uthayakumar
doaj   +1 more source

Advances in systemic treatment for adults with moderate-to-severe atopic dermatitis

Dermatologica Sinica, 2019
Atopic dermatitis (AD) is generally considered a T-helper type 2-dominated disease. Adult AD is often more severe and less manageable by topical therapies and may require systemic immunosuppressants that bear notable side effects and organ toxicities ...
Yung-Tsu Cho, Chia-Yu Chu
doaj   +1 more source

“Input/output cytokines” in epidermal keratinocytes and the involvement in inflammatory skin diseases [PDF]

, 2023
Considering the role of epidermal keratinocytes, they occupy more than 90% of the epidermis, form a physical barrier, and also function as innate immune barrier.
Kawakami, Yoshio, Morizane, Shin, Mukai, Tomoyuki, Ouchida, Mamoru, Sunagawa, Ko, Tachibana, Kota   +5 more
core   +1 more source

Role of Nemolizumab and Omalizumab in management of atopic dermatitis: A review [PDF]

, 2021
BackgroundNemolizumab (CIM331) is a monoclonal antibody that binds the IL-31 receptor α component. This inhibits IL-31 from acting on neurons that constrains the initialization of the sense of pruritus in cases of atopic dermatitis.AimsTo summarize the ...
Ahmed Bakheet N Alharbi, Ahmed Saad A Albalawi, Ali Abdulrahman A Alshehri, Ibrahim Mahmoud H Ajwah, Maram Salim S Algrani, Mohammed Abdulhafith R Alotaibi, Muneera Saeed F Alhayan, Omnia Abdulmonum A Alali, Rayyan Fahad H Altemani, Shifa Sameer A Nagadi, Shumoukh Saleh F AlAfnan, Sultan Makki M Alsharef, Yousef Ali H Alaenzi, Yousef Hussain J Alharthi, Zahra Shaker H Al-kalaif   +14 more
core   +1 more source

Assessment and Management of Atopic Dermatitis in Primary Care Settings [PDF]

, 2023
An increasingly common chronic inflammatory skin condition is atopic dermatitis (AD). It exhibits severe itching as well as recurring eczematous lesions.
Abdulaziz Khalid Albulaihed, Abdulelah Fahad Almansour, Al Hashim, Khadijah Yaseen A, Aldhafeer Eman Saad A, Ali Ibrahim Al Hussain, Almenyan, Zahra Ali, Baraah Ahmad Aldeera, Eman Ahmed M Alrashed, Ghada Hamdan Nasser Alhadidi, Mohammed Ibrahim Alsaeed, Najlaa Mohammad Alsudairy, Nawaf Abdullah Alshahrani, Renad Naif Alotaibi, Shorooq Ahmed Hamzi   +13 more
core   +3 more sources

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). [PDF]

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis.
Amato, S., Amerio, P., Arents, B.W., Argenziano, G., Aszodi, N., Avila Valle, G.L., Barbarot, S., Bieber, T., Brough, H.A., Calzavara-Pinton, P., Chiricozzi, A., Christen-Zäch, S., Corazza, M., Cusano, F., Deleuran, M., Dittmann, M., Dressler, C., Fink-Wagner, A.H., Flohr, C., Fosse, N., Gerbens, L.A., Gieler, U., Girolomoni, G., Gisondi, P., Gregoriou, S., Gáspár, K., Kinberger, M., Mortz, C.G., Naldi, L., Nast, A., Nygaard, U., Patruno, C., Pigatto, P.D., Quaglino, P., Redding, M., Rehbinder, E.M., Ring, J., Rossi, M., Serra-Baldrich, E., Simon, D., Stingeni, L., Szalai, Z.Z., Szepietowski, J.C., Tonon, F., Torrelo, A., Werfel, T., Wollenberg, A.   +46 more
core   +4 more sources